Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020

Endocrinol Metab (Seoul). 2021 Feb;36(1):41-50. doi: 10.3803/EnM.2021.106. Epub 2021 Feb 24.

Abstract

Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives. The categories of anti-diabetic medications expanded from a few to numerous, enabling clinicians to personalize diabetes care and treatment. Thanks to rapid growth in the field of science and medical engineering, newer treatment options are coming to the market with various advantages and disadvantages to be aware of. Therefore, clinicians should rapidly adopt new trends based on guidelines and data from many clinical trials in the field of diabetes. In the treatment of dyslipidemia, trends and guidelines are changing every year, and novel therapies are being developed. In this review, we would like to summarize the major achievements in clinical medicine in 2020 in the field of diabetes mellitus and dyslipidemia.

Keywords: Diabetes mellitus; Dyslipidemias; Glucagon-like peptide-1 receptor; Incretins; Insulin infusion systems; Pancreas, artificial; Sodium-glucose transporter 2 inhibitors.

Publication types

  • Review

MeSH terms

  • Clinical Medicine*
  • Diabetes Mellitus, Type 2* / drug therapy
  • Dyslipidemias* / drug therapy
  • Humans
  • Hypoglycemic Agents / therapeutic use

Substances

  • Hypoglycemic Agents